Although community-acquired pathogens have historically been susceptible to current oral agents, resistant and multiple-resistant isolates are becoming increasingly prevalent. The clinical utility of the oral^-lactam antibiotics such as oral penicillins and cephalosporins is being rapidly eroded by the increasing clinical isolation of /3-lactamaseproducing strains, due to the acquisition and transfer of plasmid-mediated determinants1'^. The emergence of isolates of methicillin-resistant Staphylococcus aureus imposes a serious limitation on the use of newer oral cephalosporins. Penem antibiotics possess the 5-lactam ring and showbroad and potent antibacterial activity against both aerobic and anaerobic Gram-positive and Gram-negative bacteria including /3-lactamase-producing strains. Although as yet only a few penems have been submitted to broad preclinical and clinical investigations, there is great interest in exploiting modifications of these compounds. Herein we report the in vitro antibacterial activity of a new penem, SUN5555 (sodium (Si^^^S.R^'^-l-Cl'-tetrahydrofuryO-G-hydroxyethylpenem-S-carboxylate, 
Materials and Methods

Bacteria
The bacterial strains used were clinical isolates collected from various hospitals in Japan and laboratory strains. All bacteria strains were stored in Nutrient Broth (Nissui Pharmaceutical Co., Ltd., Tokyo) containing 10% skim-milk at -80°C and then were maintained on Casitone Semisolid Agar (Eiken, Tokyo) or on Nutrient Agar (Nissui) with proper supplements for aerobes until used. Anaerobes were maintained in GAMAgar (Nissui).
T On leave from Simtory Institute for Biomedical Research.
SUN5555 was synthesized and purified in Suntory Institute for Biomedical Research, Osaka, Japan. Cefteram pivoxil, a prodrug formulation of cefteram, was kindly supplied from Toyama Chemical Co., Ltd., Tokyo, Japan; cefixime was from Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan; cefaclor was from Shionogi & Co., Ltd., Osaka, Japan; and other antibiotics were purchased from commercialsources. Susceptibility Testing Comparative MICs were determined by the 2-fold agar dilution method. Heart Infusion Agar (Nissui) or Sensitivity Disk Agar-N (modified Mueller-Hinton agar, Nissui) was used for the susceptibility testing of aerobic bacteria except for Branhamella catarrhalis, for which Chocolate agar containing 5 % defibrinated horse blood (Nippon Bio-Test Laboratories Inc., Japan) was used, and for Neisseria gonorrhoeae and Neisseria meningitidis for which GCAgar (Eiken) was used. GAM Agar (Nissui) was used for anaerobes. Media were supplemented with 10%of defibrinated horse blood for the testing of Streptococcus and Enterococcus sp. and 3 %Fildes enrichment (Difco Laboratories, Detroit, U.S.A.) for Haemophilus influenzae. Inocula were prepared by diluting overnight broth cultures (Sensitivity test broth or Trypto-Soya Broth, (Nissui) with proper supplements) to ca. 106 cfu/ml. Plates were inoculated with an inoculator delivering 2 [A resulting in a test inoculum of 2 x 103 cfu. Plates were incubated for 18 hours at 37°C in air, at 37°C in 5% CO2 or at 35°C anaerobically (Forma Scientific, Marietta, U.S.A.). The MICs for 50 and 90% of isolates (MIC50 and MIC90, respectively) were calculated from the cumulative percent inhibition curves.
Influence of Inoculum Size The influence of the inoculum size on the activity of SUN5555was examined by the 2-fold agar dilution method using Heart Infusion Agar. Inocula were approximately 1 x 105, 106, 107 and 108 cfu/ml of Trypto -Soya Broth medium.
Influence of the pH of Culture Medium The effect of the pH of the culture media on the activity of SUN5555was studied in Heart Infusion Agar which had been adjusted to values of pH 5.5, 7.0 and 8.5. The MICs of SUN5555 for 106 cfu/ml of the test strains were determined by the 2-fold agar dilution method.
Killing Curves The kinetics of bactericidal activity was determined for the selected test strains. An overnight broth culture was diluted into Heart Infusion Broth (Nissui) containing the indicated concentrations of the antibiotic, and cultures were incubated at 37°C with shaking. Samples of 0.1 ml were withdrawn at the times indicated, diluted with buffer and spread on antibiotic-free agar plates. The initial counts were approximately 106 cfu/ml and after 18 hours at 37°C the number of cfu/ml on each plate was counted.
The resistance to /3-lactamase of each of RGN823, Rms 213 and RGN238 was introduced to Escherichia coli KC-14 by transconjugation4).
/3-Lactamase Stability
The enzymes used were prepared by ultracentrifugation of bacterial cell extracts obtained by ultrasonication of cell suspension. The $-lactamase activity was determined by a spectrometric method*0 using a 0.1-mMconcentration of each antibiotic and was expressed in relative rate of hydrolysis, taking the rate of benzylpenicillin for penicillinases or that of cephaloridine for cephalosporinases as100.
Affinity for Penicillin-binding Proteins (PBPs)
The binding of SUN5555 to PBPs of E. coli NIH JC-2 was determined by competition with [14C]-benzylpenicillin as described6). Washed cell envelopes of E. coli were preincubated with a range of SUN5555concentrations for 10 minutes at 30°C, and the binding proteins remaining accessible to benzylpenicillin were detected by the addition of a saturating concentration of [14C]benzylpenicillin. After another 10 minutes incubation at 30°C, the binding proteins were separated on sodium dodecyl-sulfate -polyacrylamide slab gels after solubilization of the inner membranes with Sarkosyl NL-97 and quantitated by densitometry of the X-ray films.
Abbreviations
Abbreviations used in Tables and Figs, are: CCL, cefaclor; CFIX, ceflxime; CFTM,cefteram; AMPC, amoxicillin ; Pc-G, benzylpenicillin ; CER, cephaloridine; CFX, cefoxitin; CTX, cefotaxime.
Results
The Inhibitory Activity In Vitro
The inhibitory activity in vitro of SUN5555compared with four other oral antibacterial agents is shown in Tables 1 through 3 (against aerobic and facultative anaerobic bacteria) and Table 4 superior to all reference compounds. Sixty-seven %of 43 methicillin-resistant S. aureus strains are susceptible to SUN5555with MIC value below 3.13^g/ml. Against clinical isolates of Enterococci, SUN5555exhibits excellent activity, similar to that of imipenem (MIC50 : Enterococcus faecalis (30 strains) 0.78 /^g/ml, Enterococcus faecium (29 strains) 6.25 /4g/ml, Enterococcus avium (14 strains) 3.13 A*g/ml).
Membersof the Enterobacteriaceae, Neisseria species, H. influenzae and B. catarrhalis are susceptible to SUN5555and 90% of these strains are inhibited at concentrations below 1.0^g/ml. Strains of indole-negative and indole-positive Proteus species are inhibited at therapeutic concentrations. SUN5555is not active against Pseudomonas aeruginosa and exhibits varying activity against strains of Serratia marcescens. Of the compounds examined, SUN5555is the most active against all strains Influence of the Inoculum Size on the MIC The MICs of SUN5555against each of S. aureus, E. coli and Klebsiellapneumoniae were determined with different inoculum sizes. The resulting cumulative percent inhibition curves are shown in Fig. 2 . The inoculum size has little or no effect on the in vitro activity of SUN5555 against S. aureus with all sizes of inocula examined. The activity is little affected up to the inocula of 106 and 107 cfu/ml against E. coli and K. pneumoniae, respectively. The activity of SUN5555 is less affected by the inoculum sizes tested whencompared to cefaclor.
Effect of the pH of Culture Medium on the MIC From Fig. 3 , the MICs of SUN5555determined between pH 5.5 and 8.5 varied over one to three The MICs of SUN5555 (left) and CCL (right) against each of four different inoculum sizes (O 108 cfu/ml, 0 107 cfu/ml, a 106 cfu/ml, D 105 cfu/ml) of Staphylococcus aureus (7 isolates) (A), Escherichia coli (6 isolates) (B) and Klebsiella pneumoniae (7 isolates) (C) are expressed as cumulative percent inhibition curves. Fig. 3 . Effect of medium pH on antimicrobial activity.
The MICs of SUN5555 (left) and CCL(right) against each of Staphylococcus aureus (7< isolates) (A), Escherichia coli (6 isolates) (B) and Klebsiella pneumoniae (7 isolates) (C) at three different pHs of the culture media (O pH 5.5, à" pH 7.0. a pH 8.5) are expressed as cumulative percent inhibition curves. dilution steps and the profiles were comparable to that of cefaclor.
Bactericidal Activity Fig. 4 shows the bactericidal activity of SUN5555compared to other oral /3-lactams against various test organisms. The slopes of the curves in Fig. 4 demonstrate that the number of surviving *S. aureus cells decreases steadily after the addition of SUN5555in concentrations corresponding as low as 1/4 MIC. With E. coli, the addition of SUN5555at once and twice the MIC caused sharp decrease in the number of cfu in the culture. The slopes of the killing curves obtained with these concentrations of SUN5555were comparable to those of cefixime and cefteram. The bactericidal activity of SUN5555 is virtually indifferent to the genetic introduction of /3-lactamase to a test organism in contrast to that of amoxicillin7).
/3-Lactamase Stability Table 5 shows the relative rates of hydrolysis of SUN5555and other^-lactams by^-lactamases from various sources. The data indicate that SUN5555is extremely stable against all the plasmidmediated and chromosomally mediated /3-lactamases tested. The stability of SUN5555against hydrolysis by /3-lactamases is equivalent to that of cefoxitin and no significant hydrolysis of SUN5555 occurs with the chromosomally coded enzyme prepared from Bacteroides fragilis V240-2 which rapidly hydrolyzes cefotaxime.
Affinity
for PBPs As shown in Table 6 , SUN5555 binds preferentially to the PBP2 and 1A of E. coli inner membrane. These observations are consistent with the morphological effects of SUN5555on E. coli. SUN5555causes the spheroplast and bulge formation at sub-MIC concentrations and leads to bacteriolysis at the MICor above.
Discussion
SUN5555 is a novel oral synthetic penem. In contrast to cephalosporins and penicillins, the penemantibiotics have shown a unique antibacterial spectrum which includes anaerobic bacteria as well as Gram-positive and most Gram-negative pathogens8~12). These properties can also be found with the new penem SUN5555. Although it lacks the activity against Pseudomonas species, SUN5555 is muchmore potent against members of Staphylococcus and Streptococcus as well as most of Gramnegative organisms including H. influenzae, N. gonorrhoeae and B. catarrhalis than the reference oral /3-lactams, cefteram, cefixime, cefaclor and amoxicillin. SUN5555is equally active against organisms carrying the common plasmid-mediated and chromosomally mediated /3-lactamases. However, slightly higher MICsof SUN5555have been determined for Proteus species than those of cefteram and cefixime, which nevertheless should allow successful therapy of infections caused by these pathogens. The activity in vitro of SUN5555extends to some of the methicillin-resistant strains of *S. aureus. In contrast to other /3-lactams, SUN5555also exhibits marked activity against Gram-positive and Gram-negative anaerobic bacteria partly because of its stability against /3-lactamase and partly because of its intrinsic activity. A noteworthy feature of SUN5555is the narrow range of MICvalues for the susceptibility of organisms in contrast to the marked wide range of susceptibility to the newer oral cephalosporins. SUN5555could therefore be said to possess a predictable degree of antimicrobial activity against a wide range of pathogens. Since high peak levels of serum are obtained after oral administrations to mice, rabbits and dogs13) and initial results also show good chemotherapeutic activity in experimental infections, it appears that SUN5555has a remarkable potential for oral treatment of infectious diseases that are less predictably treatable with the currently available oral agents. As a role for SUN5555as an outpatient adjunct to primary parenteral therapy can be envisaged, it would be worthwhile to continue the evaluation of SUN5555.
